Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07647510 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
A Phase 3 study, sponsored by Dianthus Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 195
- Enrollment target
NCT07647510: Recruiting Phase 3 study, sponsored by Dianthus Therapeutics.
NCT07647510 is a Phase 3 study that is actively recruiting participants, run by Dianthus Therapeutics. The registered enrollment target is 195 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07647510, a Phase 3 study, is actively recruiting participants, sponsored by Dianthus Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 195 participants
- Enrollment target
Study Summary
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
Primary Outcome
The MG-ADL score is an 8-item patient reported outcome (PRO) instrument. The MG-ADL targets symptoms of disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of the MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability.
Interventions
- COMBINATION_PRODUCT Placebo
- DRUG Placebo
- DRUG Claseprubart
- COMBINATION_PRODUCT Claseprubart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-09 |
| Phase | Phase 3 |
What NCT07647510 shows while recruiting
NCT07647510 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07647510 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07647510 about?
NCT07647510 is a clinical study titled "A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)". The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
What is the current status of trial NCT07647510?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 195 participants. The study started on 2026-07. Estimated completion is 2031-09.
What interventions are being tested in trial NCT07647510?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), Placebo (DRUG), Claseprubart (DRUG), Claseprubart (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07647510?
This trial is sponsored by Dianthus Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07647510's enrollment target sits among peer trials
195 1393rd of 2000 higher than 606 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia